Tenax Therapeutics
Tenax Therapeutics maintains an oxygen supply to stop disease and damage to tissues that occurs when the flow of oxygen is interrupted.
Launch date
Employees
Market cap
AUD19.4m
Enterprise valuation
AUD5m (Public information from Sep 2024)
Share price
$3.62 TENX
Morrisville North Carolina (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | 1.0m | 4.2m |
| % growth | - | - | - | - | - | - | 316 % |
| EBITDA | (9.7m) | (32.4m) | (10.9m) | (7.7m) | - | - | - |
| Profit | (9.9m) | (32.5m) | (11.0m) | (7.7m) | (16.8m) | (23.0m) | (24.1m) |
| % profit margin | - | - | - | - | - | (2303 %) | (581 %) |
| EV / revenue | - | - | - | - | - | 13.6x | 3.3x |
| EV / EBITDA | -2.4x | -0.8x | -0.5x | -0.8x | - | - | - |
| R&D budget | 4.6m | 25.1m | 5.4m | 3.2m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| N/A | $5.4m | Post IPO Equity | |
* | N/A | $40.0m | Post IPO Equity |
| N/A | $10.0m | Post IPO Equity | |
| N/A | $5.2m | Post IPO Equity | |
| N/A | $10.0m | Post IPO Equity | |
* | N/A | $8.0m | Post IPO Equity |
* | N/A | $15.6m | Post IPO Equity |
* | N/A | $9.0m | Post IPO Equity |
* | $100m | Private Placement non VC | |
| Total Funding | AUD8.2m | ||
Related Content
Recent News about Tenax Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.